Characterization and clinical outcomes of severe asthma patients in Israel treated with benralizumab (SAIL-B)

Trial Identifier:	D3250R00126
Sponsor:	AstraZeneca
Start Date:	March 2025
Primary Completion Date:	April 2025
Study Completion Date:	April 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Israel	Tel-Aviv, Israel

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.